RCC: Molecular imaging techniques? Delayed nephrectomy?
November 6, 2023Read moreIndividualised approaches to kidney cancer were deliberated in Plenary Session 12 on the afternoon of day three at EMUC23....
00
mCRPC: Insights on Lu-PSMA, PARP inhibitors, and new targeted approaches
November 5, 2023Read moreThe second half of Plenary Session 13 “New standards and novel approaches in advanced prostate cancer” was spearheaded by...
M1a disease, systemic triplet therapy, and de-escalation strategies in HSPC
November 5, 2023Read moreThe last day of EMUC23 began with Plenary Session 13: New standards and novel approaches in advanced prostate cancer,...
New opportunities in GU cancers
November 4, 2023Read morePlenary Session 11: New opportunities in genito-urinary tumours kickstarted with the presentation “What can we learn from other tumours?”...
2023 ends with big game changers for GU cancers
November 4, 2023Read moreChaired by Prof. Axel Merseburger (DE), Prof. Karim Fizazi (FR) and Prof. Valerie Fonteyne (BE), the game-changing session on...
New NMIBC modalities in AS, systemic and intravesical therapies
November 4, 2023Read morePlenary Session 5 “Innovative concepts and new modalities of treatment in urothelial carcinomas” focused on topics such as systemic...
Shorter treatment, better imaging for high-risk PCa?
November 3, 2023Read moreCo-chaired by Assoc. Prof. Juan Gómez Rivas (ES), Prof. Peter Hoskin (GB), Assoc. Prof. Daniela Oprea-Lager (NL) and Prof....
“If you can’t measure it, you can’t improve it”
November 3, 2023Read moreDay two of EMUC23 introduced and implemented the morbidity and mortality (M&M) meeting format during the aptly-titled Plenary Session...
EMUC23: What’s new in GU screening?
November 3, 2023Read moreWhat are the novel developments in genito-urinary (GU) cancer screening? Plenary Session 1 “Genito-urinary cancer screening in 2023” explored...
